nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Malaise—Progesterone—uterine cancer	0.00482	0.00497	CcSEcCtD
Apraclonidine—Syncope—Progesterone—uterine cancer	0.0048	0.00494	CcSEcCtD
Apraclonidine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00476	0.0049	CcSEcCtD
Apraclonidine—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00475	0.00489	CcSEcCtD
Apraclonidine—Palpitations—Progesterone—uterine cancer	0.00473	0.00487	CcSEcCtD
Apraclonidine—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00471	0.00485	CcSEcCtD
Apraclonidine—Chest pain—Progesterone—uterine cancer	0.00455	0.00469	CcSEcCtD
Apraclonidine—Myalgia—Progesterone—uterine cancer	0.00455	0.00469	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00452	0.00466	CcSEcCtD
Apraclonidine—Discomfort—Progesterone—uterine cancer	0.0045	0.00463	CcSEcCtD
Apraclonidine—Ill-defined disorder—Medroxyprogesterone Acetate—uterine cancer	0.0045	0.00463	CcSEcCtD
Apraclonidine—Dry mouth—Progesterone—uterine cancer	0.00445	0.00458	CcSEcCtD
Apraclonidine—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.00437	0.0045	CcSEcCtD
Apraclonidine—Oedema—Progesterone—uterine cancer	0.00437	0.00449	CcSEcCtD
Apraclonidine—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00435	0.00447	CcSEcCtD
Apraclonidine—Infection—Progesterone—uterine cancer	0.00434	0.00446	CcSEcCtD
Apraclonidine—Pharyngitis—Dactinomycin—uterine cancer	0.00431	0.00444	CcSEcCtD
Apraclonidine—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.00428	0.00441	CcSEcCtD
Apraclonidine—Nervous system disorder—Progesterone—uterine cancer	0.00428	0.00441	CcSEcCtD
Apraclonidine—Skin disorder—Progesterone—uterine cancer	0.00424	0.00437	CcSEcCtD
Apraclonidine—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00413	0.00425	CcSEcCtD
Apraclonidine—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.00413	0.00425	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.0041	0.00422	CcSEcCtD
Apraclonidine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00408	0.0042	CcSEcCtD
Apraclonidine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00404	0.00415	CcSEcCtD
Apraclonidine—Vasodilation—Epirubicin—uterine cancer	0.00399	0.00411	CcSEcCtD
Apraclonidine—Vasodilation procedure—Epirubicin—uterine cancer	0.00399	0.00411	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00398	0.00409	CcSEcCtD
Apraclonidine—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00396	0.00407	CcSEcCtD
Apraclonidine—Insomnia—Progesterone—uterine cancer	0.00395	0.00406	CcSEcCtD
Apraclonidine—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00393	0.00405	CcSEcCtD
Apraclonidine—Paraesthesia—Progesterone—uterine cancer	0.00392	0.00404	CcSEcCtD
Apraclonidine—Dyspnoea—Progesterone—uterine cancer	0.00389	0.00401	CcSEcCtD
Apraclonidine—Somnolence—Progesterone—uterine cancer	0.00388	0.004	CcSEcCtD
Apraclonidine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00388	0.00399	CcSEcCtD
Apraclonidine—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00384	0.00396	CcSEcCtD
Apraclonidine—Lacrimation increased—Epirubicin—uterine cancer	0.00381	0.00392	CcSEcCtD
Apraclonidine—Erythema—Dactinomycin—uterine cancer	0.00378	0.00389	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Progesterone—uterine cancer	0.00377	0.00388	CcSEcCtD
Apraclonidine—Fatigue—Progesterone—uterine cancer	0.00376	0.00387	CcSEcCtD
Apraclonidine—Constipation—Progesterone—uterine cancer	0.00373	0.00384	CcSEcCtD
Apraclonidine—Pain—Progesterone—uterine cancer	0.00373	0.00384	CcSEcCtD
Apraclonidine—Vasodilation procedure—Doxorubicin—uterine cancer	0.0037	0.0038	CcSEcCtD
Apraclonidine—Vasodilation—Doxorubicin—uterine cancer	0.0037	0.0038	CcSEcCtD
Apraclonidine—Inflammation—Epirubicin—uterine cancer	0.00362	0.00372	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.0036	0.00371	CcSEcCtD
Apraclonidine—Feeling abnormal—Progesterone—uterine cancer	0.0036	0.0037	CcSEcCtD
Apraclonidine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00358	0.00368	CcSEcCtD
Apraclonidine—Coordination abnormal—Epirubicin—uterine cancer	0.00357	0.00368	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Progesterone—uterine cancer	0.00357	0.00367	CcSEcCtD
Apraclonidine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00355	0.00366	CcSEcCtD
Apraclonidine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00353	0.00363	CcSEcCtD
Apraclonidine—Lacrimation increased—Doxorubicin—uterine cancer	0.00352	0.00363	CcSEcCtD
Apraclonidine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00352	0.00362	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—uterine cancer	0.00351	0.00361	CcSEcCtD
Apraclonidine—Infestation NOS—Etoposide—uterine cancer	0.0035	0.0036	CcSEcCtD
Apraclonidine—Infestation—Etoposide—uterine cancer	0.0035	0.0036	CcSEcCtD
Apraclonidine—Dermatitis contact—Epirubicin—uterine cancer	0.00347	0.00357	CcSEcCtD
Apraclonidine—Abdominal pain—Progesterone—uterine cancer	0.00345	0.00355	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00342	0.00352	CcSEcCtD
Apraclonidine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00341	0.00351	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—uterine cancer	0.00341	0.00351	CcSEcCtD
Apraclonidine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00338	0.00348	CcSEcCtD
Apraclonidine—Inflammation—Doxorubicin—uterine cancer	0.00335	0.00345	CcSEcCtD
Apraclonidine—Coordination abnormal—Doxorubicin—uterine cancer	0.00331	0.0034	CcSEcCtD
Apraclonidine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00326	0.00336	CcSEcCtD
Apraclonidine—Dry eye—Epirubicin—uterine cancer	0.00324	0.00334	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00324	0.00333	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—uterine cancer	0.00322	0.00331	CcSEcCtD
Apraclonidine—Hypersensitivity—Progesterone—uterine cancer	0.00322	0.00331	CcSEcCtD
Apraclonidine—Dermatitis contact—Doxorubicin—uterine cancer	0.00321	0.0033	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—uterine cancer	0.00318	0.00327	CcSEcCtD
Apraclonidine—Asthenia—Progesterone—uterine cancer	0.00313	0.00322	CcSEcCtD
Apraclonidine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00313	0.00322	CcSEcCtD
Apraclonidine—Pruritus—Progesterone—uterine cancer	0.00309	0.00318	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—uterine cancer	0.00309	0.00318	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—uterine cancer	0.00307	0.00316	CcSEcCtD
Apraclonidine—Abnormal vision—Epirubicin—uterine cancer	0.00306	0.00315	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—uterine cancer	0.003	0.00309	CcSEcCtD
Apraclonidine—Diarrhoea—Progesterone—uterine cancer	0.00299	0.00307	CcSEcCtD
Apraclonidine—Eye disorder—Etoposide—uterine cancer	0.00294	0.00302	CcSEcCtD
Apraclonidine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00292	0.003	CcSEcCtD
Apraclonidine—Dizziness—Progesterone—uterine cancer	0.00289	0.00297	CcSEcCtD
Apraclonidine—Angiopathy—Etoposide—uterine cancer	0.00285	0.00294	CcSEcCtD
Apraclonidine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00284	0.00292	CcSEcCtD
Apraclonidine—Mediastinal disorder—Etoposide—uterine cancer	0.00283	0.00292	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—uterine cancer	0.00283	0.00291	CcSEcCtD
Apraclonidine—Eye pain—Epirubicin—uterine cancer	0.00282	0.0029	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00281	0.00289	CcSEcCtD
Apraclonidine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.0028	0.00288	CcSEcCtD
Apraclonidine—Vomiting—Progesterone—uterine cancer	0.00278	0.00286	CcSEcCtD
Apraclonidine—Dermatitis—Progesterone—uterine cancer	0.00275	0.00283	CcSEcCtD
Apraclonidine—Headache—Progesterone—uterine cancer	0.00274	0.00282	CcSEcCtD
Apraclonidine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00271	0.00279	CcSEcCtD
Apraclonidine—Dysgeusia—Etoposide—uterine cancer	0.00268	0.00276	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—uterine cancer	0.00266	0.00274	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—uterine cancer	0.00264	0.00272	CcSEcCtD
Apraclonidine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00269	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—uterine cancer	0.00261	0.00269	CcSEcCtD
Apraclonidine—Nausea—Progesterone—uterine cancer	0.00259	0.00267	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—uterine cancer	0.00254	0.00262	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—uterine cancer	0.00254	0.00261	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00252	0.0026	CcSEcCtD
Apraclonidine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00252	0.00259	CcSEcCtD
Apraclonidine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00249	0.00257	CcSEcCtD
Apraclonidine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00248	0.00255	CcSEcCtD
Apraclonidine—Malaise—Etoposide—uterine cancer	0.00247	0.00254	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—uterine cancer	0.00246	0.00253	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—uterine cancer	0.00244	0.00251	CcSEcCtD
Apraclonidine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00235	0.00242	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—uterine cancer	0.00233	0.0024	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00231	0.00238	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—uterine cancer	0.0023	0.00237	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—uterine cancer	0.00228	0.00234	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—uterine cancer	0.00228	0.00234	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—uterine cancer	0.00227	0.00234	CcSEcCtD
Apraclonidine—Infection—Etoposide—uterine cancer	0.00222	0.00228	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—uterine cancer	0.00221	0.00228	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—uterine cancer	0.0022	0.00227	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—uterine cancer	0.00217	0.00223	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—uterine cancer	0.00211	0.00217	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—uterine cancer	0.00211	0.00217	CcSEcCtD
Apraclonidine—ADRA2C—myometrium—uterine cancer	0.00211	0.0742	CbGeAlD
Apraclonidine—Asthma—Doxorubicin—uterine cancer	0.00204	0.0021	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—uterine cancer	0.00201	0.00206	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—uterine cancer	0.00199	0.00205	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—uterine cancer	0.00199	0.00204	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—uterine cancer	0.00196	0.00202	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—uterine cancer	0.00196	0.00202	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—uterine cancer	0.00196	0.00202	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—uterine cancer	0.00193	0.00198	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—uterine cancer	0.00193	0.00198	CcSEcCtD
Apraclonidine—Pain—Etoposide—uterine cancer	0.00191	0.00197	CcSEcCtD
Apraclonidine—Constipation—Etoposide—uterine cancer	0.00191	0.00197	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—uterine cancer	0.00191	0.00196	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—uterine cancer	0.00184	0.00189	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—uterine cancer	0.00183	0.00189	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—uterine cancer	0.00183	0.00188	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—uterine cancer	0.00182	0.00187	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—uterine cancer	0.00182	0.00187	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—uterine cancer	0.00179	0.00185	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—uterine cancer	0.00177	0.00182	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—uterine cancer	0.00177	0.00182	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—uterine cancer	0.00177	0.00182	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—uterine cancer	0.00176	0.00181	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—uterine cancer	0.00175	0.0018	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—uterine cancer	0.00174	0.00179	CcSEcCtD
Apraclonidine—ADRA1A—epithelium—uterine cancer	0.00174	0.0611	CbGeAlD
Apraclonidine—Visual impairment—Epirubicin—uterine cancer	0.0017	0.00175	CcSEcCtD
Apraclonidine—ADRA2A—myometrium—uterine cancer	0.00168	0.0592	CbGeAlD
Apraclonidine—Bradycardia—Doxorubicin—uterine cancer	0.00166	0.00171	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—uterine cancer	0.00165	0.0017	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—uterine cancer	0.00165	0.00169	CcSEcCtD
Apraclonidine—ADRA2C—uterine cervix—uterine cancer	0.00164	0.0577	CbGeAlD
Apraclonidine—Rhinitis—Doxorubicin—uterine cancer	0.00163	0.00168	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—uterine cancer	0.00163	0.00168	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—uterine cancer	0.00162	0.00167	CcSEcCtD
Apraclonidine—ADRA1A—renal system—uterine cancer	0.00161	0.0567	CbGeAlD
Apraclonidine—Oedema peripheral—Doxorubicin—uterine cancer	0.00161	0.00165	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—uterine cancer	0.0016	0.00165	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—uterine cancer	0.0016	0.00165	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—uterine cancer	0.00159	0.00163	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—uterine cancer	0.00158	0.00163	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—uterine cancer	0.00157	0.00162	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—uterine cancer	0.00157	0.00162	CcSEcCtD
Apraclonidine—ADRA2C—decidua—uterine cancer	0.00156	0.055	CbGeAlD
Apraclonidine—Mental disorder—Epirubicin—uterine cancer	0.00154	0.00159	CcSEcCtD
Apraclonidine—ADRA2C—renal system—uterine cancer	0.00153	0.054	CbGeAlD
Apraclonidine—Erythema—Epirubicin—uterine cancer	0.00153	0.00158	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—uterine cancer	0.00153	0.00157	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—uterine cancer	0.00152	0.00157	CcSEcCtD
Apraclonidine—Tension—Epirubicin—uterine cancer	0.00151	0.00155	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—uterine cancer	0.0015	0.00155	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—uterine cancer	0.00149	0.00153	CcSEcCtD
Apraclonidine—ADRA2C—endometrium—uterine cancer	0.00148	0.0522	CbGeAlD
Apraclonidine—Angiopathy—Doxorubicin—uterine cancer	0.00148	0.00152	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—uterine cancer	0.00148	0.00152	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—uterine cancer	0.00147	0.00151	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—uterine cancer	0.00146	0.0015	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—uterine cancer	0.00145	0.00149	CcSEcCtD
Apraclonidine—ADRA2C—mammalian vulva—uterine cancer	0.00143	0.0505	CbGeAlD
Apraclonidine—Mental disorder—Doxorubicin—uterine cancer	0.00143	0.00147	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—uterine cancer	0.00142	0.00147	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—uterine cancer	0.00142	0.00146	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—uterine cancer	0.00142	0.00146	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—uterine cancer	0.00141	0.00145	CcSEcCtD
Apraclonidine—Headache—Etoposide—uterine cancer	0.0014	0.00144	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—uterine cancer	0.00139	0.00143	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—uterine cancer	0.00139	0.00143	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—uterine cancer	0.00138	0.00142	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—uterine cancer	0.00138	0.00142	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—uterine cancer	0.00138	0.00142	CcSEcCtD
Apraclonidine—ADRA2C—uterus—uterine cancer	0.00137	0.0481	CbGeAlD
Apraclonidine—Palpitations—Epirubicin—uterine cancer	0.00136	0.0014	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—uterine cancer	0.00134	0.00138	CcSEcCtD
Apraclonidine—Nausea—Etoposide—uterine cancer	0.00133	0.00137	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—uterine cancer	0.00132	0.00136	CcSEcCtD
Apraclonidine—ADRA2A—uterine cervix—uterine cancer	0.00131	0.046	CbGeAlD
Apraclonidine—Myalgia—Epirubicin—uterine cancer	0.00131	0.00134	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—uterine cancer	0.00131	0.00134	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.0013	0.00134	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—uterine cancer	0.00129	0.00133	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—uterine cancer	0.00128	0.00132	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—uterine cancer	0.00128	0.00131	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—uterine cancer	0.00127	0.00131	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—uterine cancer	0.00125	0.00129	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—uterine cancer	0.00125	0.00129	CcSEcCtD
Apraclonidine—ADRA2A—decidua—uterine cancer	0.00125	0.0439	CbGeAlD
Apraclonidine—Infection—Epirubicin—uterine cancer	0.00124	0.00128	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—uterine cancer	0.00123	0.00126	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—uterine cancer	0.00122	0.00125	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—uterine cancer	0.00121	0.00124	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—uterine cancer	0.00121	0.00124	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.0012	0.00124	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—uterine cancer	0.00119	0.00123	CcSEcCtD
Apraclonidine—ADRA2A—endometrium—uterine cancer	0.00118	0.0416	CbGeAlD
Apraclonidine—Dry mouth—Doxorubicin—uterine cancer	0.00118	0.00122	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—uterine cancer	0.00116	0.00119	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—uterine cancer	0.00115	0.00118	CcSEcCtD
Apraclonidine—ADRA2A—mammalian vulva—uterine cancer	0.00115	0.0403	CbGeAlD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00114	0.00117	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—uterine cancer	0.00114	0.00117	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—uterine cancer	0.00113	0.00117	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—uterine cancer	0.00113	0.00116	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—uterine cancer	0.00112	0.00116	CcSEcCtD
Apraclonidine—ADRA2C—female gonad—uterine cancer	0.00112	0.0393	CbGeAlD
Apraclonidine—Dyspnoea—Epirubicin—uterine cancer	0.00112	0.00115	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—uterine cancer	0.00111	0.00115	CcSEcCtD
Apraclonidine—ADRA2C—vagina—uterine cancer	0.00111	0.0391	CbGeAlD
Apraclonidine—ADRA2A—uterus—uterine cancer	0.00109	0.0384	CbGeAlD
Apraclonidine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00108	0.00111	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—uterine cancer	0.00108	0.00111	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—uterine cancer	0.00107	0.0011	CcSEcCtD
Apraclonidine—Pain—Epirubicin—uterine cancer	0.00107	0.0011	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.00106	0.00109	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—uterine cancer	0.00105	0.00108	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—uterine cancer	0.00104	0.00107	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—uterine cancer	0.00103	0.00106	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—uterine cancer	0.00103	0.00106	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—uterine cancer	0.00103	0.00106	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—uterine cancer	0.00102	0.00105	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.001	0.00103	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—uterine cancer	0.000999	0.00103	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—uterine cancer	0.000991	0.00102	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—uterine cancer	0.000991	0.00102	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—uterine cancer	0.00099	0.00102	CcSEcCtD
Apraclonidine—ADRA2A—female reproductive system—uterine cancer	0.000981	0.0345	CbGeAlD
Apraclonidine—Feeling abnormal—Doxorubicin—uterine cancer	0.000955	0.000983	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000947	0.000975	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—uterine cancer	0.000922	0.000949	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—uterine cancer	0.000916	0.000943	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—uterine cancer	0.000898	0.000925	CcSEcCtD
Apraclonidine—ADRA2A—female gonad—uterine cancer	0.000892	0.0314	CbGeAlD
Apraclonidine—ADRA2A—vagina—uterine cancer	0.000887	0.0312	CbGeAlD
Apraclonidine—Pruritus—Epirubicin—uterine cancer	0.000886	0.000912	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—uterine cancer	0.000857	0.000882	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—uterine cancer	0.000854	0.000879	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—uterine cancer	0.000831	0.000856	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—uterine cancer	0.000828	0.000852	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—uterine cancer	0.00082	0.000844	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—uterine cancer	0.000796	0.000819	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—uterine cancer	0.000793	0.000816	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—uterine cancer	0.000789	0.000812	CcSEcCtD
Apraclonidine—Headache—Epirubicin—uterine cancer	0.000784	0.000807	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—uterine cancer	0.000766	0.000789	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—uterine cancer	0.000744	0.000765	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—uterine cancer	0.000737	0.000758	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—uterine cancer	0.00073	0.000751	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—uterine cancer	0.000726	0.000747	CcSEcCtD
Apraclonidine—ADRA2C—lymph node—uterine cancer	0.000719	0.0253	CbGeAlD
Apraclonidine—Nausea—Doxorubicin—uterine cancer	0.000688	0.000708	CcSEcCtD
Apraclonidine—ADRA2A—lymph node—uterine cancer	0.000574	0.0202	CbGeAlD
